128 related articles for article (PubMed ID: 167966)
1. Evaluation of the cell-mediated immune response to murine sarcoma virus by (125I)iododeoxyuridine assay and comparison with chromium 51 and microcytotoxicity assays.
Fossati G; Holden HT; Herberman RB
Cancer Res; 1975 Sep; 35(9):2600-8. PubMed ID: 167966
[TBL] [Abstract][Full Text] [Related]
2. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice.
Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H
Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223
[TBL] [Abstract][Full Text] [Related]
3. Secondary cell-mediated cytotoxic response to syngeneic mouse tumor challenge.
Holden HT; Kirchner H; Herberman RB
J Immunol; 1975 Aug; 115(2):327-31. PubMed ID: 168259
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro studies on effector cell diversity in the cellular immune response to murine sarcoma virus (MSV)-induced tumors in mice.
Plata F; Gomard E; Leclerc JC; Levy JP
J Immunol; 1974 Apr; 112(4):1477-87. PubMed ID: 4360862
[No Abstract] [Full Text] [Related]
5. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
[TBL] [Abstract][Full Text] [Related]
6. Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.
BasombrÃo MA; Mayer AM; Pasqualini CD
Cancer Res; 1977 Jun; 37(6):1768-76. PubMed ID: 192461
[TBL] [Abstract][Full Text] [Related]
7. Cell-mediated immunity to Friend virus-induced leukemia. II. Characteristics of primary cell-mediated cytotoxic response.
Ting CC; Rodgigues D; Bushar GS; Herberman RB
J Immunol; 1976 Jan; 116(1):236-43. PubMed ID: 54387
[TBL] [Abstract][Full Text] [Related]
8. Tumor inhibiting capacity of spleen and lymph node cells from mice with murine sarcoma virus (MSV-M)-induced tumors.
Weiland E; Mussgay M
Z Immunitatsforsch Exp Klin Immunol; 1975 Nov; 150(5):414-23. PubMed ID: 181922
[TBL] [Abstract][Full Text] [Related]
9. Cell-mediated immunity to Friend virus-induced leukemia. I. Modification of 125IUdR release cytotoxicity assay for use with suspension target cells.
Ting C-C ; Bushar GS; Rodrigues D; Herberman RB
J Immunol; 1975 Nov; 115(5):1351-6. PubMed ID: 170343
[TBL] [Abstract][Full Text] [Related]
10. Significance of the proline assay in the study of anti-MSV cell-mediated immune reactions.
Henin Y; Gomard E; Gisselbrecht S; Levy JP
Br J Cancer; 1979 Jan; 39(1):51-63. PubMed ID: 215185
[TBL] [Abstract][Full Text] [Related]
11. T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes.
Leclerc JC; Cantor H
J Immunol; 1980 Feb; 124(2):846-50. PubMed ID: 6243332
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody against IFN-gamma inhibits Moloney murine sarcoma virus-specific cytotoxic T lymphocyte differentiation.
Zanovello P; Vallerani E; Biasi G; Landolfo S; Collavo D
J Immunol; 1988 Feb; 140(4):1341-4. PubMed ID: 2830339
[TBL] [Abstract][Full Text] [Related]
13. Characterization of effector lymphocytes associated with immunity to murine sarcoma virus (MSV) induced tumors. I. Physical properties of cytolytic T lymphocytes generated in vitro and of their immediate progenitors.
Plata R; MacDonald HR; Engers HD
J Immunol; 1976 Jul; 117(1):52-8. PubMed ID: 180182
[TBL] [Abstract][Full Text] [Related]
14. Characterization to effector lymphocytes associated with immunity to murine sarcoma virus (MSV)-induced tumors. II. Repeated stimulation and proliferation in vitro of specific cytolytic T lymphocytes.
Plata F; Jongeneel CV
J Immunol; 1977 Aug; 119(2):623-9. PubMed ID: 196025
[No Abstract] [Full Text] [Related]
15. Antibody production and interaction with lymphoid cells in relation to tumor immunity in the Moloney sarcoma virus system.
Harada M; Pearson G; Redmon L; Winters E; Kasuga S
J Immunol; 1975 Apr; 114(4):1318-22. PubMed ID: 1090675
[TBL] [Abstract][Full Text] [Related]
16. Cell-mediated immunity to H-2 antigens. Characteristics of the effector cells as detected in the microcytotoxicity assay.
Trostmann H; Pfizenmaier K; Wagner H; Röllinghoff M
Transplantation; 1976 Jun; 21(6):446-53. PubMed ID: 1084606
[TBL] [Abstract][Full Text] [Related]
17. Specific and nonspecific antitumor immunity. I. Description of an in vitro assay based on inhibition of DNA synthesis in tumor cells.
Williams RM; Germain RN; Benacerraf B
J Natl Cancer Inst; 1975 Mar; 54(3):697-708. PubMed ID: 1091740
[TBL] [Abstract][Full Text] [Related]
18. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
[TBL] [Abstract][Full Text] [Related]
19. Generation of cytotoxic T lymphocytes during coxsackievirus B-3 infection. I. Model and viral specificity1.
Wong CY; Woodruff JJ; Woodruff JF
J Immunol; 1977 Apr; 118(4):1159-64. PubMed ID: 300399
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of mouse migration inhibitory factor (MIF) production form MSV-immune lymphocytes by soluble tumor-associated antigen: requirement for histocompatible macrophages.
Landolfo S; Herberman RB; Holden HT
J Immunol; 1977 Apr; 118(4):1244-8. PubMed ID: 191532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
